MedTech News
.................... by Andrew Celentano
Making invisible cancers visible: A new route to turn ‘cold’ tumors ‘hot’
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scientists reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells and suggests a therapeutic countermeasure: Change what the cancer displays on its surface so the immune system can recognize the tumor.
Aptitude Announces FDA 510(k) Clearance of Next-Generation Metrix® COVID Test
GOLETA, Calif., Sept. 16, 2026 /PRNewswire/ — Aptitude today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next-generation Metrix® COVID Test, marking the company’s first FDA 510(k) clearance and the continued expansion of the Metrix molecular diagnostics platform. Development was supported by the Biomedical Advanced Research and Development Authority (BARDA).
New AI technique could make minimally invasive surgeries safer and more precise
This patient-specific method, called xvr, helps doctors use X-rays for surgical navigation in fields such as orthopedics and neurosurgery.
Medtronic grabs FDA clearance to add LigaSure vessel sealer to Hugo
Medtronic (NYSE: MDT) has received an FDA green light to bring its vessel-sealing technology over to its Hugo surgical robot, adding to the platform’s U.S. catalog of energy instruments.
Neptune Medical’s robotic colonoscopy system obtains FDA clearance
Neptune Medical has landed an FDA clearance for its robotic system designed to provide stable control during colonoscopy.
CAAR T-cell therapy offers a more targeted route for neurological autoimmune diseases
Researchers at DZNE and Charité—Universitätsmedizin Berlin are working on a targeted therapy for neurological autoimmune diseases. So far, they have successfully tested their approach in mouse studies involving two such conditions. Their concept is based on deliberately modified immune cells, so-called CAAR T cells, designed to eliminate only the immune cells responsible for causing disease.
Augmented eye clinic shows why AI-native systems work where standalone algorithms don’t
AI in eye care is set to take a new leap with an AI-native rather than assisted approach. Researchers have developed a new tool that moves beyond the conventional model of deploying AI as isolated, standalone tools for individual tasks by bringing together a network of specialized AI software agents that can operate across every stage of a patient’s care pathway.
Cancer drug pushes mutant blood stem cells to become short-lived immune cells
The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators. Because the broad activity of interferon-alpha can induce significant side effects, developing more focused strategies based on these mechanistic findings could meet an important need in cancer therapy.